SAN FRANCISCO — Preemptive administration of pangenotypic direct-acting antiviral therapy resulted in rapid viral suppression of hepatitis C in patients without HCV who received a heart transplantation with an HCV-positive organ, according to data presented at The Liver Meeting 2018.

“With the rising number of HCV-positive donors, there is a time-sensitive and critical need to document both the efficacy and detailed implementation strategies surrounding successful use of HCV-positive organs,” Emily Bethea, MD, Massachusetts General Hospital, said in her presentation.